Evidence map›Paper›PMID 11836392›Full record

ArticleJournal of virology2002

Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Keith Meyer, Arnab Basu, Craig T Przysiecki, L Martin Lagging, Adrian M Di Bisceglie, Anthony J Conley, Ranjit Ray

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. New antiviral therapies for chronic hepatitis C.Hepatology international · 2010
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Keith MeyerDepartment of Internal Medicine, Saint Louis University, 3635 Vista Ave., St. Louis, Missouri 63110, USA.
Arnab Basu
Craig T Przysiecki
L Martin Lagging
Adrian M Di Bisceglie
Anthony J Conley
Ranjit Ray
United States Military Academy · USSaint Louis University · USUniversity of Gothenburg · SE

Funding

HCV ENVELOPE GYCOPROTEINS AND VACCINE DEVELOPMENTR01DK058023 · NIDDK · SAINT LOUIS UNIVERSITY · PI RAY, RANJIT · 1999 to 2003
$869k
CONTROL MEASURES IN AGING AND INFECTIOUS DISEASE-266945250N01AI045250 · NIAID · SAINT LOUIS UNIVERSITY · 1994 to 2003
$0k
NIAID NIH HHS AI 45250NIAID NIH HHS N01 AI045250NIDDK NIH HHS DK 58023NIDDK NIH HHS R01 DK058023
6 · The paper itself

Abstract

We previously reported a number of features of hepatitis C virus (HCV) chimeric glycoproteins related to pseudotype virus entry into mammalian cells. In this study, pseudotype virus was neutralized by HCV E2 glycoprotein-specific antibodies and infected human sera. Neutralization (50% reduction of pseudotype virus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concentrations of between 2.5 and 10 microg/ml. A hyperimmune rabbit antiserum to an E2 hypervariable region 1 (HVR1) mimotope also exhibited an HCV E2 pseudotype virus neutralization titer of approximately 1/50. An E1 pseudotype virus used as a negative control was not neutralized to a significant level (<1/10) by these MAbs or rabbit antiserum to E2 HVR1. Since HCV probably has a lipid envelope, the role of complement in antibody-mediated virus neutralization was examined. Significant increases in the neutralization titers of the human MAbs (approximately 60- to 160-fold higher) and rabbit antiserum to HVR1 mimotopes (approximately 10-fold higher) were observed upon addition of guinea pig complement. Further, these studies suggested that complement activation occurred primarily by the classical pathway, since a deficiency in the C4 component led to a significant decrease in the level of virus neutralization. This same decrease was not observed with factor B-deficient complement. We also determined that 9 of 56 HCV-infected patient sera (16%) had detectable pseudotype virus neutralization activity at serum dilutions of between 1/20 and 1/50 and that complement addition enhanced the neutralization activity of some of the HCV-infected human sera. Taken together, these results suggest that during infection, HCV E2 glycoprotein induces a weak neutralizing antibody response, that those antibodies can be measured in vitro by the surrogate pseudotype virus plaque reduction assay, and that neutralization function can be augmented by complement.

Indexed as

Antibody-Dependent EnhancementAntibodies, MonoclonalComplement System ProteinsHepacivirusHepatitis CHepatitis C AntibodiesHumansImmune SeraNeutralization TestsRecombinant Fusion ProteinsViral Envelope ProteinsAntibodies, MonoclonalComplement System Proteinsglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesImmune SeraRecombinant Fusion ProteinsViral Envelope Proteins

Identifiers

PMID11836392
PMCPMC153822
OpenAlexW2130904640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.